Leriglitazone
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Dec 8, 2017 (NCT03231878)
Timeline
Indications
Mechanism of action
PPARG activator
Peroxisome proliferator-activated receptor gamma agonist
Chemistry & pharmacology
Loading structure…
SMILES
CC(O)c1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1- Mol. weight
- 372.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1267 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05819866 | Phase 3 | Jul 12, 2023 | Minoryx Therapeutics, S.L. |
| NCT04528706 | Phase 2 | Sep 13, 2019 | Minoryx Therapeutics, S.L. |
| NCT03917225 | Phase 2 | Mar 26, 2019 | Minoryx Therapeutics, S.L. |
| NCT03231878 | Phase 2/Phase 3 (Phase 3) | Dec 8, 2017 | Minoryx Therapeutics, S.L. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Minoryx Therapeutics, S.L. | For profit | 4 | 4 | 2 | 2017 |
1 organizations
Page 1 / 1